Danggui Hongzao Keli (当归红枣颗粒)当归红枣颗粒
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
生产企业Manufacturer
- 甘肃兰药药业有限公司Chinese legal name: 甘肃兰药药业有限公司
主要成分Active Ingredients
- 当归Dang Gui
- 红枣Hong Zao
药物知识说明
当归是一种在国家药监局注册认定的药品。该药品含有当归、红枣-d7a03db1等成分。
该药品关联的活性成分包括：当归Dang Gui、红枣Hong Zao。这些成分信息来自国家药监局数据库。
该药品标注的生产企业为：甘肃兰药药业有限公司Chinese legal name: 甘肃兰药药业有限公司。
您可以探索含有相同成分的其他药品：当归-955c5af6成分药品。
本页面内容来自国家药监局数据库，MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 当归红枣颗粒) is a medicine registered with the national drug regulatory authority. It contains recorded ingredients as active ingredient(s).
Active ingredients associated with this product: 当归Dang Gui, 红枣Hong Zao.
Manufacturers recorded for this product: 甘肃兰药药业有限公司Chinese legal name: 甘肃兰药药业有限公司.
Explore other medicines containing the same ingredient: 当归 productsProducts containing this recorded ingredient.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 当归红枣颗粒Recorded Chinese name: 当归红枣颗粒
- 剂型Dosage form: 颗粒剂Granules
- 规格Specification: 每袋装20g20 g per sachet
本段仅展示注册/说明书已记录的身份属性，不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
主要成分Ingredients
生产企业Manufacturer
- 甘肃兰药药业有限公司Chinese legal name: 甘肃兰药药业有限公司
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字Z62020980
关联实体Relationships
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
- 剂型来源Dosage-form source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录（非改写、非AI摘要），非正式英文标签，亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字Z62020980
Manufacturer
Chinese legal name: 甘肃兰药药业有限公司 (domestically manufactured)
Traditional functions
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Precautions
English translation unavailable. The original Chinese source label remains available below.
Storage
Keep tightly closed.
Specification
English translation unavailable. The original Chinese source label remains available below.
中文说明书原文Original Chinese source label
批准文号
国药准字Z62020980
生产企业
甘肃兰药药业有限公司(国产)
功能主治
养血调经。用于月经量少，色淡。
用法用量
口服，一次1袋，一日２－３次。
不良反应
尚不明确。
禁忌
忌食生冷油腻饮食。
注意事项
1.忌食生冷油腻饮食。
2.服本药时不宜和感冒药同时服用。
3.合并贫血者应在医师指导下服用。
4.糖尿病患者服药前应向医师咨询。
5.服用一个月经周期症状无改善者，应向医师咨询。
6.按照用法用量服用，服药过程中出现不良反应，应停药，并向医师咨询。
7.对本品过敏者禁用，过敏体质者慎用。
8.本品性状发生改变时禁止使用。
9.请将本品放在儿童不能接触的地方。
10.如正在使用其他药品，使用本品前请咨询医师或药师。
贮藏
密闭保存。
规格
每袋装20g
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.